Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease

NCT06844565 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT06844565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06844565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease
Lead sponsor
Tanta University
Phase
Observational
Overall status
Completed
Start date
January 1, 2021
Completion date
December 31, 2023
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biomarker, crohn disease, diagnosis, interleukin 12, interleukin 23